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Banitt, Peter F., Paul Smits, Stephen B. Williams, channels contribute to reactive hyperemia in the fore- 
Peter Ganz, and Mark A. Creager. Activation of ATP- arm of healthy humans.sensitive potassium channels contributes to reactive hyper­emia in humans. A?n. J. Physiol. 271 (Heart Circ. Physiol. 40): H1594-H1598, 1996.—Activation of ATP-sensitive potas­sium ( K a t p )  channels present on vascular smooth muscle cells causes membrane hyperpolarization and vasodilation. The purpose of this study was to determine whether Katp chan­nels contribute to reactive hyperemia in humans. Accord-
Adenosine has been implicated as a substance that 
mediates reactive hyperemia. During ischemia, the 
interstitial concentration of adenosine increases as a 
consequence of ATP metabolism. Adenosine stimulates 
specific membrane receptors of the Pr purinergic type. 
A subtype of these adenosine receptors, the Ax receptor,
ingly, we studied the effect of tolbutamide, a channel has been reported to be coupled to channels (11?inhibitor, on reactive hyperemic forearm blood flow. Forearm 22). Indeed, several, but not all, studies in animal blood flow was measured by venous occlusion plethysmogra- models have suggested that adenosine induces vasodi-
27).phy. Forearm ischemia was produced by inflating a sphygmo- lation via KATP channel activation (3, 18, 24 manometric cuff on the arm to suprasystolic pressures for 5 Therefore, a second objective of this study was tomin. After cuff release, forearm blood flow was measured during the reactive hyperemic phase for 5 min. TolbutamidemM blood concentration, n did not affect basal(2.4 ± 0.2 to 2.2 ± 0.1 ml* 100 ml 1-min”1) or peak reactive hyperemic forearm blood flow (21.9 ± 3.8 to 22.6 ± 2.9 ml -100NS), but it significantly attenuatedml i •mm l each
determine whether KATp channel inhibition with tolbu­
tamide attenuates the vasodilator effects of adenosine. 
Endothelium-derived nitric oxide also contributes to 
reactive hyperemia in humans (19, 25, 31). Further 
more, one study suggested that vasodilation in re­
total hyperemic volume (12.6 ± 1.7 vs. 9.2 ± 1.8 ml/100 ml, sponse to endothelium-derived nitric oxide may in part P < 0.02). Vehicle (n
reactive hyperemic flow, or total hyperemia. To determine tion of K a tp  channels (32). Thus a third objective was towhether adenosine or endothelium-derived nitric oxide con­tribute to reactive hyperemia via K Atp  channels, adenosine (1.5-500 pg/min, n = 6) and acetylcholine (30 pg/min, n
did not affect basal flow, peak be via membrane hyperpolarization secondary to activa
=  6 )were infused before and during tolbutamide coinfusion. Tolbu­tamide did not significantly alter the forearm blood flow response to either adenosine or acetylcholine. In conclusion,channels contribute to vasodilation during reactive hyperemia in humans.
determine whether the endothelium-dependent vasodi-
lator acetylcholine activates K Atp channels.
METHODS
Subjects. Eighteen healthy volunteers were recruited toparticipate in this study. The study subjects included nine males and nine females, 22-45 years of age (averagingadenosine; ischemia; nitric oxide; regional blood flow; tolbuta- 32.6 ± 1.5 yr). Each volunteer’s health status was assessed mide by history, physical examination, and laboratory analysis ofserum lipid and glucose levels. None of the subjects had clinical evidence of systemic disease, and none used tobaccoproducts. This study was approved by the Human Research 
IMMEDIATELY FOLLOWING THE RELEASE of an arterial Committee of Brigham and Women’s Hospital, and each
occlusion, blood flow rapidly increases and then slowly 
returns to basal values. The vasodilation that consti­
tutes this reactive hyperemia has been attributed to 
myogenic factors (4) and/or the release of a number of 
vasoactive substances, including adenosine (5, 7, 13), 
prostaglandins (8, 21), and endothelium-derived nitric
oxide (25, 31, 35). Recently, studies in animal models vascular research laboratory was quiet, and lights were dimmed, 
have found that vascular smooth muscle membrane All subjects rested at least 30 min after catheter placement to 
hyperpolarization, mediated by activation of ATP- establish a stable baseline before data acquisition.
subject gave written informed consent.General procedures. Each subject was studied in the supine position in a 23°C temperature-controlled room in the postab- sorptive state. Alcohol and caffeine were not permitted within the preceding 12 h. Using sterile technique and local anesthesia, we inserted a 20-gauge polyethylene catheter into the brachial artery for blood pressure monitoring and drug infusion. The
sensitive potassium (Katp) channels, contributes to 
blood flow regulation during reactive hyperemia (1,14,
20). Whether KATP channels contribute to reactive 
hyperemia in humans is not known. Sulfonylurea com­
pounds are specific KATP channel inhibitors (16, 30, 34)
that are used to treat patients with non-insulin- 
dependent diabetes mellitus. We used tolbutamide, a
Hemodynamic measurements. Bilateral forearm blood flow was determined by venous occlusion strain-gauge plethysmog­raphy using calibrated mercury-in-Silastic strain gauges (D. E. Hokanson, Issaquah, WA) and is expressed as milliliter per 100 milliliters tissue per minute. Each arm was supported above heart level. The venous occlusion pressure was 40 mmHg. Hand blood flow was prevented during measure­ments by inflating a cuff at the wrist to suprasystolic levels.
sulfonylurea that is available in parenteral form for Each forearm blood flow determination consisted of at least
human use, to test the primary hypothesis that KATP five separate measurements performed at 10- to 15-s inter-
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Fig. 2. Effect of tolbutamide and vehicle on total reactive hyperemia. 
Tolbutamide, but not vehicle, significantly reduced total reactive
hyperemia. *P <0.02.
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Fig. 4. Effect of tolbutamide on acetylcholine-induced changes in 
forearm blood flow. Blood flow response to acetylcholine was not
affected by acetylcholine (P ttnlUiaiìi NS).
5.9 -t- 0.7 uU/ml, P npiiwiliww NS).
Effects of tolbutamide on adenosine and acetylcholine- 
induced vasodilation. Adenosine (1.5-500 p.g/min) in­
creased forearm blood flow incrementally from a basal
value of 2.0 ± 0.3 to 15.2 ± 2.7 ml-100 m l^-m in"1. 
Tolbutamide did not affect the forearm blood flow 
response to adenosine (Fig. 3). Acetylcholine (30 ug/ 
min) increased forearm blood flow from 2.5 ± 0.2 to 
14.0 ± 2.8 ml* 100 ml ^m in 3 and decreased forearm 
vascular resistance from 34.3 ± 2.8 to 7.3 ± 2.2 units. 
The vasodilator effects of acetylcholine were not inhib­
ited by tolbutamide (Fig. 4).
DISCUSSION
The important new finding in this study is that tolbutamide, a KATP-channel inhibitor, attenuates reac­tive hyperemic blood flow in the human forearm. Tolbu­tamide did not affect peak reactive hyperemic bloodflow, but it did significantly reduce total hyperemic
volume. Additionally, we found that adenosine-induced 
vasodilation is not inhibited by tolbutamide infusion, 
indicating that adenosine does not activate K At p  chan-
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Fig. 3. Effect of tolbutamide on forearm blood flow dose-response 
curve to adenosine. Adenosine increased forearm blood flow in a 
dose-dependent manner. Tolbutamide did not affect forearm blood 
flow response to adenosine CP = NS). O, Before, and ♦, during
nels during reactive hyperemia. Finally, tolbutamide 
did not affect vasodilation in response to the endothe- 
lium-dependent vasodilator acetylcholine, suggesting 
that endothelium-derived nitric oxide does not activate 
K ATp channels.Vascular smooth muscle membrane hyperpolariza- 
tion. Vascular smooth muscle tone is regulated by 
intracellular calcium concentrations (17). Important 
determinants of intracellular calcium regulation are 
voltage-dependent calcium channels that respond to 
changes in transmembrane potential of vascular smooth 
muscle cells. Three types of potassium channels may 
induce membrane hyperpolarization and thereby affect 
voltage-dependent calcium channels: calcium-acti- 
vated potassium channels, delayed rectifier potassium 
channels, and KAtp channels.
In 1983, Noma (28) first reported the presence of 
potassium-selective ion channels that were inhibited 
by normal cytosolic concentrations of ATP. In ATP- 
depleted states, such as myocyte ischemia, these chan­
nels are activated, resulting in membrane hyperpolar­
ization. Sulfonylurea compounds such as tolbutamide 
and glibenclamide (16, 29, 30) have been shown to 
specifically inhibit KATP channels. In this study, tolbuta-
mide was chosen to block the effects of Katp channels
because its parenteral form is available for use in 
humans. In vitro studies have demonstrated that tolbu­
tamide in the range of 1 mM inhibits KATp channels and 
blocks vasodilation (15, 30). Therefore, we adjusted our 
intra-arterial tolbutamide infusions such that the net 
concentration of tolbutamide in the brachial artery was 
mM. Protein binding may have decreased the free 
tolbutamide concentration (2); however, pilot studies 
with higher tolbutamide infusion concentrations re- 
suited in hypoglycemia.
Contribution of K ^p channels to reactive hyperemia.
Evidence derived from experimental animal models 
supports the hypothesis that KATP are involved in regulat­
ing vascular smooth muscle tone during reactive hyper 
emia. Aversano et al. (1) reported that glibenclamide 
administered into the circumflex coronary artery of
open-chest anesthetized dogs decreased reactive
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hyperemia by 50% after a 30-s coronary occlusion, dependent hyperpolarizing factor hyperpolarizes the 
Duncker et al. (14) made similar observations in con- vascular smooth muscle and results in vasodilation (6,
scious dogs. Kanatsuka et al. (20), using a floating 10, 26, 32). Some, but not all, studies suggest that
objective microscope to observe canine coronary epicar- KAtp channels mediate this hyperpolarization (6 10*
dial microvessels, reported that intracoronary glibencl- 29). This study does not directly assess whether the
amide (200 p.g/kg) significantly blunted microvascular endothelium is involved in vascular smooth muscle
vasodilation after a 30-s coronary occlusion. This attenu- hyperpolarization. However, the fact that acetylcholine-
ation of vasodilation was most marked in vessels <100 induced vasodilation is not affected by tolbutamide
p.m in diameter but was present in all vessels studied, suggests that nitric oxide release does not activate KAtp
Similarly, canine diaphragmatic reactive hyperemic channels in the human forearm.
flow and duration is also significantly blunted by Physiological implications. In this study, tolbuta-
glibenclamide (8 X 10“~5 M) (33). In addition to reactive mide infusion did 
hyperemia, KATp channels have been shown to mediate
«Jit w ’1M\ Ah
the vasodilation seen in response to other stimuli such 
as hypoxia and decreased perfusion pressure. Using an emic stimulus are not dependent onmsms channel
isolated guinea pig heart model, Dautetal. (12) demon- activation. However, tolbutamide did attenuate total
strated that hypoxia-induced coronary artery vasodila- reactive hyperemia, indicating that K Atp channel acti- 
tion is prevented by glibenclamide. Similarly, using an
isolated rabbit heart model, Nakhostine and Lamon- phase of reactive hyperemia.
tagne (27) observed that glibenclamide significantly Other factors are involved in mediating reactive
attenuated hypoxia-induced vasodilation. Komaru et hyperemic blood flow in humans, including nitric oxide 
al. (23) reported that topical glibenclamide abolished prostaglandins, and adenosine; the relative contribu- 
vasodilation of epicardial arteries during periods of tion of these factors may vary from the peak to the
reduced perfusion pressure. sustained phase of reactive hyperemia. We have found
In this study we report that KATP channels also are previously that nitric oxide contributes to peak and
operative in the human vasculature, because tolbuta- total reactive hyperemic blood flow, but others have 
mide significantly blunted the total reactive hyperemic
flow. The degree of total reactive hyperemia inhibition
(27% compared with control) is somewhat less than
that observed in many of the animal models cited
above.Adenosine-induced vasodilation. Many investigators 
have suggested that adenosine is a mediator of vasodi-
reported that nitric oxide is involved only in the sus­
tained response (19, 25, 31). Inhibition of prostanoid
production with cyclooxygenase inhibitors has been 
reported to blunt peak reactive hyperemic flow in
humans in two studies (7, 21) but not in another (19).
is
lation during reactive hyperemia (5, 13 35). Evi-
dence that adenosine can directly activate KATP chan­
nels has been found in some, but not all, studies (3, 11, 
18, 24, 27). We sought to determine whether the 
decrease in total reactive hyperemic flow during tolbu­
tamide infusion implicated a reduction in adenosine-
When these observations are taken together, 
apparent that a number of mediators contribute to 
reactive hyperemia in human limb resistance vessels. 
The relative contribution of each in human health
gation
This research was supported by National in ■<.*
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TPnde did not inhibit forearm vasodilation to adenosine;
this that the effects of adenosine are not
mediated via Ka?p channels in human forearm resis­
tance vessels. The lack of effect of tolbutamide on 
adenosine-induced vasodilation does not eliminate aden­
osine as a participant in reactive 
adenosine can cause vasodilation by other mechanisms 
such as direct activation of adenosine receptors on 
vascular smooth muscle.
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Endothelium-dependent vasodilation. The vascular 
endothelium can elaborate a number of potent vasoac­
tive substances, including nitric oxide and a yet uniden­
tified hyperpolarizing factor (6, 9, 10, 26, 32). Previous 
studies in humans have demonstrated that nitric oxide
inhibition with iVG-monomethyl-L-arginine (l-NMMA)
reduces total reactive hyperemia (19 25 31) Most
evidence suggests that the action of nitric oxide is via 
activation of guanylyl cyclase and increased production 
of guanosine 3',5'-cyclic monophosphate; however, ni­
tric oxide also may cause vasodilation through vascular 
smooth muscle hyperpolarization (32). Endothelium-
REFERENCES
1. Aver sano, T., P. Ouyang, and H. Silverman.
4- * #
the canine2. Ayanoglu, G., M. Uihlein, and II. G
Then Toxicol, 24: 653. Belloni, F. L., and T. H è *
J. Phymol i r v .-, IX A., W. E.
lea, 69: ■mm
H1598 CHANNELS AND REACTIVE HYPEREMIA
5. Bockman, E. L., R. M. Berne, and R. Rubio. Adenosine and 21. Kilbom, A., and A. Wennmalm. Endogenous prostaglandins as
local regulators of blood flow in man: effect of indomethacin on
reactive functional J. Physiol. Lotici. 257109-121,1976.
active hyperemia in dog skeletal muscle. Am. J. Physiol. 230 1531-1537,1976.6. Brayden, J. E. Membrane hyperpolarization is a mechanism o 
endothelium-dependent cerebral vasodilation. Am. J.259 (Heart Circ. Physiol. 28): H668-H673,1990.7. Carlsson, I., A. Sollevi, and A. Wennmalm. The role of 
myogenic relaxation, adenosine and prostaglandins in human
forearm reactive hyperaemia. J. Physiol. Land. 389: 147-161, 23. Komaru, T., K. G. Lamping, C. L. Eastham, and K. C
1987. Dellsperger. Role of ATP-sensitive potassium channels in coro-8. Carlsson, I., and A. Wennmalm. Effect of different prostaglan­
din synthesis inhibitors on post-occlusive blood flow in human 
forearm. Prostaglandins 26: 241-252,1983.
22, Kirsch, G. E., J. Codina, L. Birnbaumer, and A. M. Brown.
Coupling of ATP-sensitive K 1 channels to Ai receptors by G 
proteins in rat ventricular myocytes. Am. J . Physiol. 259 (Heart
Circ. Physiol 28): H820-H826,1990.
9. Chen, G. F., and D. W. Cheung. Characterization of acetylcho
nary microvascular regulatory responses. Circ. Res. 69: 1146-1151,1991.24. Makujina, S. R., H. A. Olanrewaju, and S. J. Mustafa.
* nline-induced membrane hyperpolarization in
Circ. Res. 70: 257-263,1992.10. Chen, G., Y. Yamamoto, K. Miwa, and H. Suzuki. Hyperpolar
# dilation of epicardial vessels. Am. J. 
(Heart Circ. Physiol. 36): H716-H724,1994.
267
c
29
substances. Am,. J. Physiol. 260 (Heart Circ. Physiol. 29): H1888- H1892, 1991.11. Dart, C., and N. B. Standen. Adenosine-activated potassiun
current in smooth muscle cells isolated from the pig coronary
artery. J. Physiol Lond. 471: 768-789,1995.12. Daut, J., W. Maier-Rudolph, N. von Beckerath, G. MehrkeK. Gunther, and L. Goedel-Meinen. Hypoxic dilation of coro­nary arteries isScience Wash. DC 247:1341-1344,1990.13. Dobson, J. G. Jr., R. Rubio, and R. M. Berne. Role
adenosine nucleotides, adenosine, and inorganic phosphate 
the regulation of skeletal muscle blood flow. Circ375-384,1971.14. Duncker, D. J., N. S. Van Zon, J. D. Altman, T. J. Pavek, andR. J. Bache. Role of K atp channels in coronary vasodilation 
during exercise. Circulation 88:1245-1253,1993.15. Gasser, R., W. Klein, and E. Kickenweiz. Vasodilative re­
sponse to hypoxia and simulated ischemia is mediated by ATP-
sensitive K+ channels in guinea pig thoracic aorta. Angiology 44:228-243, 1993.16. Gillis, K. D., W. M. Gee, A. Hammoud, M. L. McDaniel, L. C.Falke, and S. Misler. Effects of sulfonamides on a metabolite- 
regulated ATPj-sensitive K+ channel in rat pancreatic p-cells. 
Am. J. Physiol 257 (Cell Physiol 26): C1119-C1127,1989.17. Hathaway, D. R., K. L. March, J. A. Lash, and L. P. Adam.
25. Meredith, I. T., K. E. Currie, T. J. Anderson, M. Roddy, P.Ganz, and M. A. Creager. Postischemic vasodilation in human 
forearm is dependent on endothelium-derived nitric oxide. Am. J.
Physiol 270 (Heart Circ. Physiol 39): H1435-H1440,1996.. Nagao, T., and P. M. Vanhoutte.
coronary artery. J. Physiol. Lond. 445: 355-367, 1992.27. Nakhostine, N., and D. Lamontagne. Adenosine contributes
chan-34):nel activation. Am. J. 
H1289-H1293,1993.
265 (Heart Circ.
28. Noma, A. ATP-regulated K l channels in cardiac muscle. Nature
Lond. 305:147-148,1983.29. Standen, N. B., J. M. Quayle, N. W. Davies, J. E. Brayden, Y.Huang, and M. T. Nelson. Hyperpolarizing vasodilators acti­
vate ATP-sensitive K+ channels in arterial smooth muscle. 
Science Wash. DC 245:177-180,1989.30. Sturgess, N. C., M. L. J. Ashford, D. L. Cook, and C. N.Hales. The sulphonylurea receptor may be an ATP-sensitive 
potassium channel. Lancet 453: 474-475, 1985.31. Tagawa, T., T. Imaizumi, T. Endo, M. Shiramoto, Y. Ha-rasawa, and A. Takeshita. Role of nitric oxide in reactive 
hyperemia in human forearm vessels. Circulation 90:2290,1994.32. Tare, M., H. C. Parkington, H. A. Coleman, T. O. Neild, and
G. J. Dusting. Hyperpolarization and relaxation
Vascular smooth A review the molecular basis of382-390,1991.18. Jackson, Ln J¿r
M ♦
Circ. Physiol 34): H1797-H1803,1993.
by activity
. J. Physiol 265 {Heart
lium. Nature Lond. 346: 69-71,1990. 33. Vanelli, G., and S. N. Hussain.
19. Joannides, R., W. E. Haefeli, L. Linder, V. Richard, E. H.
blockers on basal vascular tone and reactive hyperemia of canine 
diaphragm. Am. J. Physiol 266 (Heart Circ. Physiol. 35): H43- 
H51, 1994.
Bakkali, C. Thuillez, and T. F. Ltischer. Nitric oxide is 34. Venkatesh, N., S. T. Lamp, and J. N. Weiss.
channels, and cellular K 1
conduit arteries in vivo. Circulation 91: 1314-1319,1995. Kanatsuka, H., N. Sekiguchi, K. Sato, K. Akai, Y. Wang, T. Komaru, K. Ashikawa, and T. Takishima. Microvascular
in
coronary circulation of the beating canine heart. Circ. Res. 71:
912-
1Res. 69:623-637,1991.Yamabe, H., K. Okumura, H. Ishizaka, T. Tsuchiya, and H. Yasue. Role of endothelium-derived nitric oxide
H14, 1992.
